Cybin Inc. Transfers to Nasdaq, Changes Ticker to HELP
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 18 2025
0mins
Should l Buy ?
Source: Businesswire
- Market Transition: Cybin Inc. announced its voluntary transfer from NYSE American to Nasdaq effective January 5, 2026, marking a significant step in the company's evolution within the global pharmaceutical sector, which is expected to enhance market recognition and investor confidence.
- Brand Revitalization: Upon listing on Nasdaq, the company will operate under the name Helus Pharma, aiming to better reflect its commitment to innovation in mental healthcare, thereby attracting increased attention and investment.
- Liquidity Enhancement: The move to Nasdaq is anticipated to improve the liquidity of Cybin's shares, as Nasdaq has a broader investor base, potentially providing more opportunities for future financing and expansion.
- R&D Progress: With CYB003 and CYB004 in Phase 3 and Phase 2 clinical trials respectively, the transition to Nasdaq will help elevate the visibility of Cybin's R&D projects, attracting potential partners and investors to support its innovative drug development efforts.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
